Is there a preferred sequence of therapy in renal cell carcinoma?

For many years, sunitinib and pazopanib have been the standard first line therapy for metastatic clear cell RCC. A new treatment paradigm is now evolving. Longer overall survival and higher response rate of nivolumab/ipilumimab and pembrolizumab/axitinib combinations vs. sunitinib were demonstrated ...

There is no one preferred sequence for all patients. Certainly, IO-based combinations are standard, and in my opinion, should be given to all pts unless an IO contraindication. There are advantages and disadvantages to IO/IO vs IO/TKI, and usually, MD preference drives this decision taking into acco...